Thrombophilia and pregnancy complications

Khare, 2003, Acquired thrombophilias and pregnancy, Best Pract Res Clin Obstet Gynaecol, 17, 491, 10.1016/S1521-6934(03)00013-0 Gharavi, 2001, Mechanisms of pregnancy loss in antiphospholipid syndrome, Clin Obstet Gynecol, 44, 11, 10.1097/00003081-200103000-00003 Vinatier, 2001, Antiphospholipid syndrome and recurrent miscarriages, Eur J Obstet Gynecol Reprod Biol, 96, 37, 10.1016/S0301-2115(00)00404-8 Clark, 1998, Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy, Thromb Haemost, 79, 1166, 10.1055/s-0037-1615035 Bremme, 1992, Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium, Obstet Gynecol, 80, 132 Kjellberg, 1999, APC resistance and other haemostatic variables during pregnancy and puerperium, Thromb Haemost, 81, 527, 10.1055/s-0037-1614518 Comp, 1986, Functional and immunologic protein S levels are decreased during pregnancy, Blood, 68, 881, 10.1182/blood.V68.4.881.881 Eichinger, 1999, Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden, Thromb Haemost, 82, 1232, 10.1055/s-0037-1614366 Regan, 2000, Epidemiology and the medical causes of miscarriage, Baillieres Best Pract Res Clin Obstet Gynaecol, 14, 839, 10.1053/beog.2000.0123 Brenner, 2000, Inherited thrombophilia and fetal loss, Curr Opin Hematol, 7, 290, 10.1097/00062752-200009000-00006 Kupferminc, 1999, Increased frequency of genetic thrombophilia in women with complications of pregnancy, N Engl J Med, 340, 9, 10.1056/NEJM199901073400102 Brenner, 1999, Inherited thrombophilia and pregnancy loss, Thromb Haemost, 82, 634, 10.1055/s-0037-1615890 Press, 2002, Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders, Arch Pathol Lab Med, 126, 1304, 10.5858/2002-126-1304-CUOFVL Brenner, 1999, Thrombophilic polymorphisms are common in women with fetal loss without apparent cause, Thromb Haemost, 82, 6, 10.1055/s-0037-1614620 Ridker, 1998, Factor V Leiden mutation as a risk factor for recurrent pregnancy loss, Ann Intern Med, 128, 1000, 10.7326/0003-4819-128-12_Part_1-199806150-00007 Grandone, 1997, Factor V Leiden is associated with repeated and recurrent unexplained fetal losses, Thromb Haemost, 77, 822, 10.1055/s-0038-1656060 Martinelli, 2000, Mutations in coagulation factors in women with unexplained late fetal loss, N Engl J Med, 343, 1015, 10.1056/NEJM200010053431405 Gris, 1999, Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent—the Nimes Obstetricians and Haematologists Study 5 (NOHA5), Thromb Haemost, 81, 891, 10.1055/s-0037-1614594 Raziel, 2001, Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss, Am J Reprod Immunol, 45, 65, 10.1111/j.8755-8920.2001.450201.x Foka, 2000, Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages, Hum Reprod, 15, 458, 10.1093/humrep/15.2.458 Reznikoff-Etievan, 2001, Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage, BJOG, 108, 1251 Rai, 1996, Second-trimester pregnancy loss is associated with activated C resistance, Br J Haematol, 92, 489, 10.1046/j.1365-2141.0000.d01-1465.x Younis, 2000, Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss, Am J Reprod Immunol, 43, 31, 10.1111/j.8755-8920.2000.430106.x Tal, 1999, A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure, Hum Reprod, 14, 1624, 10.1093/humrep/14.6.1624 Wramsby, 2000, Primary habitual abortions are associated with high frequency of factor V Leiden mutation, Fertil Steril, 74, 987, 10.1016/S0015-0282(00)01545-4 Dizon-Townson, 1997, Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction, Am J Obstet Gynecol, 177, 402, 10.1016/S0002-9378(97)70205-9 Kutteh, 1999, Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss, Fertil Steril, 71, 1048, 10.1016/S0015-0282(99)00133-8 Alfirevic, 2001, Postnatal screening for thrombophilia in women with severe pregnancy complications, Obstet Gynecol, 97, 753, 10.1016/S0029-7844(01)01190-5 Hashimoto, 1999, The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion, Hum Reprod, 14, 1872, 10.1093/humrep/14.7.1872 Dizon-Townson, 1997, The factor V Leiden mutation is not a common cause of recurrent miscarriage, J Reprod Immunol, 34, 217, 10.1016/S0165-0378(97)00039-9 Pabinger, 2000, Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden, Hematol J, 1, 37, 10.1038/sj.thj.6200005 Volzke, 2003, Factor V Leiden and the risk of stillbirth in a German population, Thromb Haemost, 90, 429, 10.1160/TH03-02-0117 Hohlagschwandtner, 2003, Combined thrombophilic polymorphisms in women with idiopathic recurrent miscarriage, Fertil Steril, 79, 1141, 10.1016/S0015-0282(02)04958-0 Tormene, 1999, The risk of fetal loss in family members of probands with factor V Leiden mutation, Thromb Haemost, 82, 1237, 10.1055/s-0037-1614367 Preston, 1996, Increased fetal loss in women with heritable thrombophilia, Lancet, 348, 913, 10.1016/S0140-6736(96)04125-6 Meinardi, 1999, Increased risk for fetal loss in carriers of the factor V Leiden mutation, Ann Intern Med, 130, 736, 10.7326/0003-4819-130-9-199905040-00013 Murphy, 2000, Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy, Arterioscler Thromb Vasc Biol, 20, 266, 10.1161/01.ATV.20.1.266 Rey, 2003, Thrombophilic disorders and fetal loss: a meta-analysis, Lancet, 361, 901, 10.1016/S0140-6736(03)12771-7 de Visser, 1999, A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis, Blood, 93, 1271, 10.1182/blood.V93.4.1271 Rodeghiero, 1999, Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism, Ann Intern Med, 130, 643, 10.7326/0003-4819-130-8-199904200-00004 Rai, 2001, Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage, Hum Reprod, 16, 961, 10.1093/humrep/16.5.961 Sarig, 2002, Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage, Fertil Steril, 77, 342, 10.1016/S0015-0282(01)02971-5 Gris, 1997, Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study, Thromb Haemost, 77, 1096, 10.1055/s-0038-1656119 Clark, 2001, The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: significance of pregnancy associated activated protein C resistance, Thromb Haemost, 85, 30, 10.1055/s-0037-1612659 Poort, 1996, A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis, Blood, 88, 3698, 10.1182/blood.V88.10.3698.bloodjournal88103698 Pihusch, 2001, Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester, Am J Reprod Immunol, 46, 124, 10.1111/j.8755-8920.2001.460202.x Souza, 1999, Factor V leiden and factor II G20210A mutations in patients with recurrent abortion, Hum Reprod, 14, 2448, 10.1093/humrep/14.10.2448 Morrissey, 2002, Management of thrombophilia in renal transplant patients, Am J Transplant, 2, 872, 10.1034/j.1600-6143.2002.20910.x Pickering, 2001, G20210A prothrombin gene mutation: prevalence in a recurrent miscarriage population, Clin Appl Thromb Hemost, 7, 25, 10.1177/107602960100700106 Carp, 2002, Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss, Hum Reprod, 17, 1633, 10.1093/humrep/17.6.1633 Fatini, 2000, Angiotensin-converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility, Blood Coagul Fibrinolysis, 11, 657, 10.1097/00001721-200010000-00010 Many, 2002, Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia, Obstet Gynecol, 99, 684, 10.1016/S0029-7844(02)01938-5 Sanson, 1996, The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women, Thromb Haemost, 75, 387, 10.1055/s-0038-1650282 Perry, 1999, Hyperhomocysteinaemia, Baillieres Best Pract Res Clin Haematol, 12, 451, 10.1053/beha.1999.0036 den Heijer, 1996, Hyperhomocysteinemia as a risk factor for deep-vein thrombosis, N Engl J Med, 334, 759, 10.1056/NEJM199603213341203 Eichinger, 1998, Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism, Thromb Haemost, 80, 566 Gris, 2003, Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study, Blood, 102, 3504, 10.1182/blood-2003-01-0320 Kumar, 2003, Plasma homocysteine levels correlated to interactions between folate status and methylene tetrahydrofolate reductase gene mutation in women with unexplained recurrent pregnancy loss, J Obstet Gynaecol, 23, 55, 10.1080/0144361021000043263 Nelen, 2000, Homocysteine and folate levels as risk factors for recurrent early pregnancy loss, Obstet Gynecol, 95, 519, 10.1016/S0029-7844(99)00610-9 Coumans, 1999, Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion, Hum Reprod, 14, 211, 10.1093/humrep/14.1.211 Quere, 1998, A woman with five consecutive fetal deaths: case report and retrospective analysis of hyperhomocysteinemia prevalence in 100 consecutive women with recurrent miscarriages, Fertil Steril, 69, 152, 10.1016/S0015-0282(97)00451-2 Vollset, 2000, Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study, Am J Clin Nutr, 71, 962, 10.1093/ajcn/71.4.962 Nelen, 2000, Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis, Fertil Steril, 74, 1196, 10.1016/S0015-0282(00)01595-8 Nelen, 2000, Maternal homocysteine and chorionic vascularization in recurrent early pregnancy loss, Hum Reprod, 15, 954, 10.1093/humrep/15.4.954 Gindler, 2001, Folic acid supplements during pregnancy and risk of miscarriage, Lancet, 358, 796, 10.1016/S0140-6736(01)05969-4 Quere, 2001, Vitamin supplementation and pregnancy outcome in women with recurrent early pregnancy loss and hyperhomocysteinemia, Fertil Steril, 75, 823, 10.1016/S0015-0282(01)01678-8 Unfried, 2002, The C677T polymorphism of the methylenetetrahydrofolate reductase gene and idiopathic recurrent miscarriage, Obstet Gynecol, 99, 614, 10.1016/S0029-7844(01)01789-6 van der Molen, 2000, Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy, BJOG, 107, 785, 10.1111/j.1471-0528.2000.tb13341.x Holmes, 1999, The C677T MTHFR gene mutation is not predictive of risk for recurrent fetal loss, Br J Haematol, 105, 98, 10.1111/j.1365-2141.1999.01319.x Haverkate, 1995, Familial dysfibrinogenemia and thrombophilia: report on a study of the SSC Subcommittee on Fibrinogen, Thromb Haemost, 73, 151, 10.1055/s-0038-1653741 Gris, 2002, High frequency of protein Z deficiency in patients with unexplained early fetal loss, Blood, 99, 2606, 10.1182/blood.V99.7.2606 Franchi, 2001, Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss, Br J Haematol, 114, 641, 10.1046/j.1365-2141.2001.02964.x Glueck, 2001, Genetic hypofibrinolysis in complicated pregnancies, Obstet Gynecol, 97, 44, 10.1016/S0029-7844(00)01094-2 Yamada, 2000, Factor XII deficiency in women with recurrent miscarriage, Gynecol Obstet Invest, 49, 80, 10.1159/000010220 Laude, 2001, Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight, Thromb Haemost, 85, 18, 10.1055/s-0037-1612657 Dossenbach-Glaninger, 2003, Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss, Clin Chem, 49, 1081, 10.1373/49.7.1081 Alonso, 2002, Acquired and inherited thrombophilia in women with unexplained fetal losses, Am J Obstet Gynecol, 187, 1337, 10.1067/mob.2002.126849 Younis, 2000, The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation, BJOG, 107, 415, 10.1111/j.1471-0528.2000.tb13240.x Gris, 2003, Anti-protein Z antibodies in women with pathologic pregnancies, Blood, 101, 4850, 10.1182/blood-2002-12-3802 Grandone, 1999, Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria, Thromb Haemost, 81, 349, 10.1055/s-0037-1614475 Kupferminc, 2000, Severe preeclampsia and high frequency of genetic thrombophilic mutations, Obstet Gynecol, 96, 45, 10.1016/S0029-7844(00)00861-9 Mello, 1999, Usefulness of screening for congenital or acquired hemostatic abnormalities in women with previous complicated pregnancies, Haemostasis, 29, 197 van Pampus, 1999, High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia, Am J Obstet Gynecol, 180, 1146, 10.1016/S0002-9378(99)70608-3 von Tempelhoff, 2000, Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets, Thromb Res, 100, 363, 10.1016/S0049-3848(00)00312-1 D'Elia, 2002, Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia, Gynecol Obstet Invest, 53, 84, 10.1159/000052998 Morrison, 2002, Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review, Thromb Haemost, 87, 779, 10.1055/s-0037-1613083 De Groot, 1999, Preeclampsia and genetic risk factors for thrombosis: a case-control study, Am J Obstet Gynecol, 181, 975, 10.1016/S0002-9378(99)70335-2 Livingston, 2001, Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia, Am J Obstet Gynecol, 185, 153, 10.1067/mob.2001.114691 Pabinger, 2001, Preeclampsia and fetal loss in women with a history of venous thromboembolism, Arterioscler Thromb Vasc Biol, 21, 874, 10.1161/01.ATV.21.5.874 Grandone, 1997, Factor V Leiden, C>T MTHFR polymorphism and genetic susceptibility to preeclampsia, Thromb Haemost, 77, 1052, 10.1055/s-0038-1656110 Dizon-Townson, 1996, The factor V Leiden mutation may predispose women to severe preeclampsia, Am J Obstet Gynecol, 175, 902, 10.1016/S0002-9378(96)80022-6 Rigo, 2000, Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5, 10 methylenetetrahydrofolate reductase, Hypertens Pregnancy, 19, 163, 10.1081/PRG-100100132 Kupferminc, 2002, Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia, BJOG, 109, 1373, 10.1046/j.1471-0528.2002.02194.x Agorastos, 2002, Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome, J Matern Fetal Neonatal Med, 12, 267, 10.1080/jmf.12.4.267.273 Kobashi, 1999, The factor V Leiden mutation is not a common cause of pregnancy-induced hypertension in Japan, Semin Thromb Hemost, 25, 487, 10.1055/s-2007-994955 Lindoff, 1997, Preeclampsia is associated with a reduced response to activated protein C, Am J Obstet Gynecol, 176, 457, 10.1016/S0002-9378(97)70515-5 Currie, 2002, Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia?, BJOG, 109, 191 Kim, 2001, Am J Obstet Gynecol, 184, 1211, 10.1067/mob.2001.110411 Benedetto, 2002, Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome, Acta Obstet Gynecol Scand, 81, 1095, 10.1034/j.1600-0412.2002.811201.x Paternoster, 2002, Activated protein C resistance in normal and pre-eclamptic pregnancies, Gynecol Obstet Invest, 54, 145, 10.1159/000067878 Hira, 2003, Absence of factor V Leiden, thrombomodulin and prothrombin gene variants in black South African women with pre-eclampsia and eclampsia, BJOG, 110, 327, 10.1046/j.1471-0528.2003.01090.x O'Shaughnessy, 1999, Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort, Hypertension, 33, 1338, 10.1161/01.HYP.33.6.1338 Lindqvist, 1998, Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss—a possible evolutionary selection mechanism, Thromb Haemost, 79, 69, 10.1055/s-0037-1614222 Schlembach, 2003, Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction, Clin Sci (Lond), 105, 279, 10.1042/CS20030073 Lindqvist, 1999, Activated protein C resistance (FV:Q506) and pregnancy, Thromb Haemost, 81, 532, 10.1055/s-0037-1614519 Kupferminc, 2000, High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss, Acta Obstet Gynecol Scand, 79, 963, 10.3109/00016340009169243 Higgins, 2000, Prothrombin G20210A mutation: is it associated with pre-eclampsia?, Gynecol Obstet Invest, 50, 254, 10.1159/000010326 Prasmusinto, 2002, The methylenetetrahydrofolate reductase 677 C—>T polymorphism and preeclampsia in two populations, Obstet Gynecol, 99, 1085, 10.1016/S0029-7844(02)01997-X Kobashi, 2000, Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and preeclampsia in Japanese women, Am J Med Genet, 93, 122, 10.1002/1096-8628(20000717)93:2<122::AID-AJMG8>3.0.CO;2-Z Laivuori, 2000, 677 C—>T polymorphism of the methylenetetrahydrofolate reductase gene and preeclampsia, Obstet Gynecol, 96, 277, 10.1016/S0029-7844(00)00896-6 Kaiser, 2001, C677T methylenetetrahydrofolate reductase polymorphism is not a risk factor for pre-eclampsia/eclampsia among Australian women, Hum Hered, 51, 20, 10.1159/000022954 Powers, 2003, The 677 C-T methylenetetrahydrofolate reductase mutation does not predict increased maternal homocysteine during pregnancy, Obstet Gynecol, 101, 762, 10.1016/S0029-7844(02)03120-4 Lachmeijer, 2001, Mutations in the gene for methylenetetrahydrofolate reductase, homocysteine levels, and vitamin status in women with a history of preeclampsia, Am J Obstet Gynecol, 184, 394, 10.1067/mob.2001.109393 Rajkovic, 1999, Plasma homocyst(e)ine concentrations in eclamptic and preeclamptic African women postpartum, Obstet Gynecol, 94, 355, 10.1016/S0029-7844(99)00304-X Hogg, 2000, Second-trimester plasma homocysteine levels and pregnancy-induced hypertension, preeclampsia, and intrauterine growth restriction, Am J Obstet Gynecol, 183, 805, 10.1067/mob.2000.109044 Powers, 1998, Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation, Am J Obstet Gynecol, 179, 1605, 10.1016/S0002-9378(98)70033-X Laivuori, 1999, Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia, Obstet Gynecol, 93, 489, 10.1016/S0029-7844(98)00527-4 Sanchez, 2001, Plasma folate, vitamin B(12), and homocyst(e)ine concentrations in preeclamptic and normotensive Peruvian women, Am J Epidemiol, 153, 474, 10.1093/aje/153.5.474 Powers, 2001, Homocysteine and cellular fibronectin are increased in preeclampsia, not transient hypertension of pregnancy, Hypertens Pregnancy, 20, 69, 10.3109/10641950109152643 Murakami, 2001, The relation between plasma homocysteine concentration and methylenetetrahydrofolate reductase gene polymorphism in pregnant women, J Obstet Gynaecol Res, 27, 349, 10.1111/j.1447-0756.2001.tb01284.x Cotter, 2001, Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia, Am J Obstet Gynecol, 185, 781, 10.1067/mob.2001.117304 Cotter, 2003, Elevated plasma homocysteine in early pregnancy: a risk factor for the development of nonsevere preeclampsia, Am J Obstet Gynecol, 189, 391, 10.1067/S0002-9378(03)00669-0 Sorensen, 1999, Elevated second-trimester serum homocyst(e)ine levels and subsequent risk of preeclampsia, Gynecol Obstet Invest, 48, 98, 10.1159/000010148 Hietala, 2001, Serum homocysteine at 16 weeks and subsequent preeclampsia, Obstet Gynecol, 97, 527, 10.1016/S0029-7844(00)01197-2 Zeeman, 2003, Homocysteine plasma concentration levels for the prediction of preeclampsia in women with chronic hypertension, Am J Obstet Gynecol, 189, 574, 10.1067/S0002-9378(03)00543-X Martinelli, 2001, Familial thrombophilia and the occurrence of fetal growth restriction, Haematologica, 86, 428 Grandone, 2002, Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A(20210) mutations, Haematologica, 87, 177 Leeda, 1998, Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction, Am J Obstet Gynecol, 179, 135, 10.1016/S0002-9378(98)70263-7 Clark, 1999, Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight, Lancet, 353, 292, 10.1016/S0140-6736(05)74935-7 Infante-Rivard, 2002, Absence of association of thrombophilia polymorphisms with intrauterine growth restriction, N Engl J Med, 347, 19, 10.1056/NEJM200207043470105 Wiener-Megnagi, 1998, Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae, Am J Obstet Gynecol, 179, 1565, 10.1016/S0002-9378(98)70025-0 Facchinetti, 2003, Thrombophilic mutations are a main risk factor for placental abruption, Haematologica, 88, 785 Goddijn-Wessel, 1996, Hyperhomocysteinemia: a risk factor for placental abruption or infarction, Eur J Obstet Gynecol Reprod Biol, 66, 23, 10.1016/0301-2115(96)02383-4 Prochazka, 2003, Factor V Leiden in pregnancies complicated by placental abruption, BJOG, 110, 462, 10.1046/j.1471-0528.2003.02369.x Hira, 2002, Polymorphisms in various coagulation genes in black South African women with placental abruption, BJOG, 109, 574, 10.1111/j.1471-0528.2002.01528.x Many, 2001, Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia, Obstet Gynecol, 98, 1041, 10.1016/S0029-7844(01)01621-0 Mousa, 2000, Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?, Hum Reprod, 15, 1830, 10.1093/humrep/15.8.1830 Gopel, 2001, Selection pressure for the factor-V-Leiden mutation and embryo implantation, Lancet, 358, 1238, 10.1016/S0140-6736(01)06354-1 Vern, 2000, Frequency of factor V(Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions, Hum Pathol, 31, 1036, 10.1053/hupa.2000.16281 Hundsdoerfer, 2003, Homozygous and double heterozygous Factor V Leiden and Factor II G20210A genotypes predispose infants to thromboembolism but are not associated with an increase of foetal loss, Thromb Haemost, 90, 628, 10.1160/TH03-02-0096 von Kries, 2001, Foetal growth restriction in children with prothrombotic risk factors, Thromb Haemost, 86, 1012, 10.1055/s-0037-1616526 Gopel, 1999, Prothrombotic mutations as a risk factor for preterm birth, Lancet, 353, 1411, 10.1016/S0140-6736(99)00665-0 Eitzman, 2002, Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden, Circulation, 105, 2139, 10.1161/01.CIR.0000017361.39256.82 Kutteh, 1996, Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone, Am J Obstet Gynecol, 174, 1584, 10.1016/S0002-9378(96)70610-5 Rai, 1997, Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies), BMJ, 314, 253, 10.1136/bmj.314.7076.253 Grandone, 2002, Preventing adverse obstetric outcomes in women with genetic thrombophilia, Fertil Steril, 78, 371, 10.1016/S0015-0282(02)03222-3 Brenner, 2000, Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin, Thromb Haemost, 83, 693, 10.1055/s-0037-1613894 Carp, 2003, Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia, J Thromb Haemost, 1, 433, 10.1046/j.1538-7836.2003.00066.x Tzafettas, 2002, Thromboprophylaxis throughout pregnancy in women with previous history of recurrent miscarriages of unknown aetiology, Clin Exp Obstet Gynecol, 29, 267 Sanson, 1999, Safety of low-molecular-weight heparin in pregnancy: a systematic review, Thromb Haemost, 81, 668, 10.1055/s-0037-1614550 Bar, 2001, Effect of thrombophylaxis on uterine and fetal circulation in pregnant women with a history of pregnancy complications, Thromb Res, 101, 235, 10.1016/S0049-3848(00)00413-8 Brenner, 2002, Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss, Blood, 100, 2765 Brenner, 2003, Enoxaparin treatment improves the gestational outcome of pregnant women with thrombophilia and recurrent pregnancy loss: The LIVE-ENOX Study, Blood, 102 Riyazi, 1998, Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study, Eur J Obstet Gynecol Reprod Biol, 80, 49, 10.1016/S0301-2115(98)00083-9 Kupferminc, 2001, Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias, Hypertens Pregnancy, 20, 35, 10.3109/10641950109152640